Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash from Investing Activities (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Cash from Investing Activities for 3 consecutive years, with -$7000.0 as the latest value for Q3 2025.

  • Quarterly Cash from Investing Activities rose 97.17% to -$7000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$28000.0 through Dec 2025, up 98.92% year-over-year, with the annual reading at -$28000.0 for FY2025, 98.92% up from the prior year.
  • Cash from Investing Activities for Q3 2025 was -$7000.0 at Inhibrx Biosciences, up from -$21000.0 in the prior quarter.
  • The five-year high for Cash from Investing Activities was -$7000.0 in Q3 2025, with the low at -$3.4 million in Q4 2023.
  • Average Cash from Investing Activities over 3 years is -$859750.0, with a median of -$529000.0 recorded in 2023.
  • Peak annual rise in Cash from Investing Activities hit 99.54% in 2024, while the deepest fall reached 69.54% in 2024.
  • Over 3 years, Cash from Investing Activities stood at -$3.4 million in 2023, then surged by 99.54% to -$16000.0 in 2024, then surged by 56.25% to -$7000.0 in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$7000.0, -$21000.0, and -$16000.0 for Q3 2025, Q1 2025, and Q4 2024 respectively.